Get the Stockscreener App
48.73
2.42%
-1.21
Veracyte Inc stock is traded at $48.73, with a volume of 1.17M.
It is down -2.42% in the last 24 hours and up +47.80% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$49.94
Open:
$49.44
24h Volume:
1.17M
Relative Volume:
1.15
Market Cap:
$3.89B
Revenue:
$541.74M
Net Income/Loss:
$88.01M
P/E Ratio:
44.86
EPS:
1.0862
Net Cash Flow:
$155.34M
1W Performance:
+5.16%
1M Performance:
+47.80%
6M Performance:
+9.24%
1Y Performance:
+80.62%
1-Day Range:
$47.95
$49.75
1-Week Range:
$44.93
$50.54
52-Week Range:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
48.73 | 3.98B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
FMR LLC holds 8.06M Veracyte (VCYT) shares, representing 10.1% - Stock Titan
Veracyte Insider Sold Shares Worth $6,919,585, According to a Recent SEC Filing - marketscreener.com
Veracyte CFO Rebecca Chambers sells $177,082 in company stock By Investing.com - Investing.com Canada
Veracyte global chief commercial off sells $699,732 in stock By Investing.com - Investing.com Canada
Veracyte EVP Annie McGuire sells $158k in company stock By Investing.com - Investing.com Canada
Veracyte CEO Marc Stapley sells $6.9m in company shares By Investing.com - Investing.com Canada
Veracyte CFO Rebecca Chambers sells $177,082 in company stock - Investing.com
Veracyte (VCYT) CFO trades shares as RSUs vest and 10b5-1 plan executes - Stock Titan
Veracyte (VCYT) CCO sells 13,975 shares under 10b5-1 plan, keeps 132K - Stock Titan
Veracyte global chief commercial off sells $699,732 in stock - Investing.com
Veracyte CEO Marc Stapley sells $6.9m in company shares - Investing.com
[144] VERACYTE, INC. SEC Filing - stocktitan.net
VCYT (NASDAQ) insider 10b5-1 sale of 10,204 shares; 3,176 RSUs registered - Stock Titan
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call - Yahoo Finance
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report? - Yahoo Finance
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate CancerSlideshow (NASDAQ:VCYT) 2026-06-03 - Seeking Alpha
Veracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
Veracyte stock price target maintained at $42 by Canaccord on study results - Investing.com
Veracyte (VCYT) Launches Prosigna Breast Cancer Risk Test in the U.S. - GuruFocus
Wolfe Research initiates Veracyte stock coverage with Outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates Veracyte stock coverage with Outperform rating - Investing.com
VCYT Maintained by Needham -- Price Target Raised to $57.00 - GuruFocus
Needham raises Veracyte stock price target to $57 on trial data By Investing.com - Investing.com South Africa
Needham raises Veracyte stock price target to $57 on trial data - Investing.com Australia
Veracyte (VCYT) Launches Prosigna Breast Risk Test for Cancer Pr - GuruFocus
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Veracyte launches Prosigna breast cancer test in U.S. By Investing.com - Investing.com Australia
Veracyte Inc Investor Call on ASCO Findings Transcript - GuruFocus
Veracyte launches Prosigna breast cancer test in U.S. - Investing.com
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S. - standard-journal.com
Veracyte Inc stock (US92347M1009): Nasdaq diagnostics name steadies after recent gains - AD HOC NEWS
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer - BioSpace
Breast and prostate cancer test data: Veracyte schedules June 1 call - Stock Titan
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy - BioSpace
Veracyte (VCYT) Unveils Promising Findings from Enzamet Trial - GuruFocus
Veracyte Says Enzamet Trial Shows Decipher Prostate Test Identifies Chemotherapy Benefit In Metastatic Prostate Cancer - TradingView
Study shows which prostate cancer patients can safely skip chemotherapy - Stock Titan
Here's how much you'd have if you invested $1000 in Veracyte a decade ago - MSN
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Ve - The National Law Review
A Look at Veracyte Inc (VCYT) After 7.8% Gain -- GF Value $37.84 vs Price $47.99 - GuruFocus
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform (NASDAQ:VCYT) - Seeking Alpha
Veracyte chief accounting officer sells $1.09m in stock By Investing.com - Investing.com Nigeria
Veracyte chief accounting officer sells $1.09m in stock - Investing.com
Veracyte (VCYT) CAO exercises options and sells 24,000 shares in Form 4 filing - Stock Titan
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now? - TradingView
Veracyte genomic test identifies breast cancer patients who can skip chemo - whbl.com
How Veracyte Inc. (VCYT) Affects Rotational Strategy Timing - Stock Traders Daily
Here's why Veracyte (VCYT) is a strong momentum stock - MSN
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Veracyte Inc Stock (VCYT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chambers Rebecca | Chief Financial Officer |
Jun 04 '26 |
Sale |
49.73 |
3,561 |
177,083 |
173,280 |
| Stapley Marc | Chief Executive Officer |
Jun 04 '26 |
Option Exercise |
36.60 |
138,051 |
5,052,667 |
578,545 |
| Stapley Marc | Chief Executive Officer |
Jun 04 '26 |
Sale |
50.12 |
138,051 |
6,919,585 |
440,494 |
| Leite John | Global Chief Commercial Off |
Jun 04 '26 |
Sale |
50.07 |
13,975 |
699,732 |
132,305 |
2.13%
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):